BBIO · Insider Trading
BridgeBio Pharma, Inc. Common Stock
Every open-market purchase and sale reported by BBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Neil Kumar | Chief Executive Officer | Sell | −10,000 | −$690.85K |
| 2026-08-20 | Neil Kumar | Chief Executive Officer | Sell | −44,980 | −$3.73M |
| 2026-08-18 | Maricel Apuli | Chief Accounting Officer | F | −4,714 | −$376.46K |
| 2026-08-18 | Thomas Trimarchi | President and CFO | F | −22,781 | −$1.82M |
| 2026-08-18 | Neil Kumar | Chief Executive Officer | MIXED | +34,980 | −$2.89M |
| 2026-08-03 | Maricel Apuli | Chief Accounting Officer | Sell | −2,000 | −$160.12K |
| 2026-07-13 | Andrea Ellis | Director | MIXED | — | −$1.15M |
| 2026-07-13 | Jennifer E. Cook | Director | MIXED | — | −$9.45M |
| 2026-06-24 | James C Momtazee | Director | A | +3,990 | — |
| 2026-06-24 | Andrea Ellis | Director | A | +3,990 | — |
| 2026-06-24 | Hannah Valantine | Director | MIXED | +1,794 | −$224.35K |
| 2026-06-24 | Fred Hassan | Director | A | +3,990 | — |
| 2026-06-24 | Andrew Lo | Director | A | +3,990 | — |
| 2026-06-24 | Ali J. Satvat | Director | A | +3,990 | — |
| 2026-06-24 | Douglas A. Dachille | Director | A | +3,990 | — |
| 2026-06-24 | Eric Aguiar | Director | A | +3,990 | — |
| 2026-06-24 | Ronald J Daniels | Director | A | +3,990 | — |
| 2026-06-24 | Frank McCormick | Director | A | +3,990 | — |
| 2026-06-24 | Charles J Homcy | Director | A | +3,990 | — |
| 2026-06-24 | Jennifer E. Cook | Director | MIXED | +1,794 | −$2.30M |
| 2026-06-23 | Charles J Homcy | Director | F | −788 | −$52.22K |
| 2026-06-17 | Jennifer E. Cook | Director | MIXED | −7,152 | −$5.17M |
| 2026-06-08 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$5.41M |
| 2026-05-26 | Neil Kumar | Chief Executive Officer | Sell | −26,103 | −$1.81M |
| 2026-05-19 | Randal W. Scott | Director | MIXED | — | −$503.96K |
| 2026-05-19 | Maricel Apuli | Chief Accounting Officer | F | −4,714 | −$311.74K |
| 2026-05-19 | Neil Kumar | Chief Executive Officer | MIXED | +34,979 | −$2.40M |
| 2026-05-19 | Thomas Trimarchi | President and CFO | MIXED | −36,432 | −$2.39M |
| 2026-05-11 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$5.39M |
| 2026-05-04 | Maricel Apuli | Chief Accounting Officer | Sell | −2,000 | −$143.16K |
| 2026-04-13 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$5.97M |
| 2026-03-20 | Maricel Apuli | Chief Accounting Officer | A | +14,170 | — |
| 2026-03-20 | Thomas Trimarchi | President and CFO | A | +59,041 | — |
| 2026-03-19 | Neil Kumar | Chief Executive Officer | A | +144,883 deriv. | — |
| 2026-03-16 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$5.50M |
| 2026-03-12 | Hannah Valantine | Director | MIXED | — | −$387.07K |
| 2026-03-06 | Andrea Ellis | Director | MIXED | — | −$3.66M |
| 2026-03-03 | Hannah Valantine | Director | MIXED | — | −$483.08K |
| 2026-02-27 | Maricel Apuli | Chief Accounting Officer | Sell | −2,000 | −$132.00K |
| 2026-02-23 | Neil Kumar | Chief Executive Officer | Sell | −28,053 | −$2.00M |
| 2026-02-18 | Maricel Apuli | Chief Accounting Officer | MIXED | −4,859 | −$365.16K |
| 2026-02-18 | Randal W. Scott | Director | MIXED | — | −$587.06K |
| 2026-02-18 | Neil Kumar | Chief Executive Officer | MIXED | +33,728 | −$2.33M |
| 2026-02-18 | Thomas Trimarchi | President and CFO | MIXED | −32,419 | −$2.43M |
| 2026-02-12 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$5.75M |
| 2026-01-12 | Neil Kumar | Chief Executive Officer | Sell | −80,000 | −$6.04M |
| 2025-12-16 | Thomas Trimarchi | President and CFO | F | −13,826 | −$1.04M |
| 2025-12-16 | Maricel Apuli | Chief Accounting Officer | F | −2,003 | −$150.53K |
| 2025-12-16 | Neil Kumar | Chief Executive Officer | MIXED | — | −$4.57M |
| 2025-12-10 | Maricel Apuli | Chief Accounting Officer | Sell | −2,000 | −$148.52K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| KKR Genetic Disorder L.P. | 10%+ Owner | 19,260,971 | $1.31B |
| Ole Andreas Halvorsen | 10%+ Owner | 18,555,375 | $1.26B |
| KKR & Co. Inc. | 10%+ Owner | 13,260,971 | $903.74M |
| Neil Kumar | Chief Executive Officer | 993,327 | $67.70M |
| Charles J Homcy | Director | 919,876 | $62.69M |
| Frank McCormick | Director | 767,244 | $52.29M |
| Thomas Trimarchi | President and CFO | 336,529 | $22.93M |
| Ali J. Satvat | Director | 169,983 | $11.58M |
| Maricel Apuli | Chief Accounting Officer | 122,687 | $8.36M |
| Brian C Stephenson | CFO and Treasurer | 110,964 | $7.56M |
| James C Momtazee | Director | 99,070 | $6.75M |
| Andrew Lo | Director | 68,662 | $4.68M |
| Andrea Ellis | Director | 39,746 | $2.71M |
| Douglas A. Dachille | Director | 30,579 | $2.08M |
| Fred Hassan | Director | 29,879 | $2.04M |
| Jennifer E. Cook | Director | 27,383 | $1.87M |
| Ronald J Daniels | Director | 20,981 | $1.43M |
| Randal W. Scott | Director | 19,389 | $1.32M |
| Eric Aguiar | Director | 10,579 | $720.96K |
| Hannah Valantine | Director | 9,657 | $658.12K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.